



ELSEVIER
SAUNDERS

Crit Care Clin 20 (2004) 325–328

CRITICAL
CARE
CLINICS

Index

Note: Page numbers of article titles are in **boldface** type.

A

- Acute normovolemic hemodilution, 290–291
- Age
 - as factor in blood transfusions, 286–287
- Allergic transfusion reaction
 - transfusions in ICU and, 241
- Alloimmunization
 - platelet
 - transfusions in ICU and, 244
- Anaphylactic transfusion reactions
 - transfusions in ICU and, 241
- Anemia
 - adaptation to, 190–195
 - bleeding-related, 165
 - hemolytic, 164–165
 - in cancer patients, 166–168
 - in critically ill patients, **159–178**, **225–235**
 - erythropoiesis and, 160–162
 - hematocrit in, 172–173
 - hemodilution in, 172–173
 - physiologic response and, 168–171
 - transfusion for, 171
 - in high-risk groups, 227–228
 - in ICU, 299–301
 - adaptation to, 300
 - impairment to adaptive mechanisms in, 300–301
 - pathophysiology of, 299–300
 - inflammation and, 162–164
 - iron-deficiency, 164
 - microcirculatory effects of, 195–196
 - pathophysiologic processes and interaction between, 196–202
 - physiologic aspects of, **187–212**
 - renal failure due to, 166
 - tolerance of
 - physiologic response and, 168–171
 - transfusions for
 - adaptation to, 190–195
 - benefits of, 228–233
 - uncorrected
 - natural history of, 225–227

- Anemia and Blood Transfusion in Critical Care (ABC) trial, 180–181, 256
- Anemia of critical illness
 - phlebotomy and, 314–316
- Arterial venous catheters
 - in anemia of critical illness, 315

B

- Bleeding-related anemia, 165
- Blood conservation
 - for critically ill patients, **313–324**
 - appropriate transfusion thresholds in, 319–320
 - blood substitutes in, 319
 - pharmacologic hemostasis in, 318–319
 - point-of-care bedside microanalysis in, 317
 - RBC salvage techniques in, 317–318
 - recombinant human erythropoietin in, 318
 - small volume phlebotomy tubes in, 316
 - techniques for
 - evaluation of, 320–321
 - incorporation of, 320–321
- Blood substitutes
 - in blood conservation, 319
 - in transfusions, 289–290
- Blood transfusion(s)
 - current practice in, **179–186**
 - studies of
 - common themes among, 183
 - studies related to, 179–185
 - Anemia and Blood Transfusion in Critical Care (ABC) trial, 180–181
 - CRIT trial, 181–182
 - good practice of, 183–185

- in military situations, 282–283
 - in surgery, **281–296**
 - age-related effects on, 286–287
 - blood substitutes in, 289–290
 - bloodless surgery centers, 293
 - critical care issues, 283–284
 - damage control surgery, 293
 - effects of, 285–286
 - elective surgery, 284
 - emergency-related, 284–285
 - history of, 281–282
 - intraoperative blood recovery, 291–292
 - “less-blood surgery,” 292–293
 - in trauma
 - age-related effects on, 286–287
 - blood substitutes in, 289–290
 - effects of, 285–286
 - emergency-related, 284–285
 - Blood transfusion thresholds
 - in blood conservation, 319–320
 - Bloodless surgery centers, 293
- C**
-
- Cancer
 - anemia in patients with, 166–168
 - Cardiac contractility
 - compromised
 - transfusions in, 271
 - Cardiac patients
 - transfusion in, **269–279**. *See also Transfusion(s), in cardiac patients.*
 - Cardio–respiratory events
 - transfusions in ICU and, 241–242
 - Catheter(s)
 - arterial venous
 - in anemia of critical illness, 315
 - central venous
 - in anemia of critical illness, 315
 - Central venous catheters
 - in anemia of critical illness, 315
 - Children
 - transfusions in, **299–311**. *See also Transfusion(s), in children.*
 - CMV. *See Cytomegalovirus (CMV).*
 - Coronary artery disease
 - transfusions in, 270–271
 - Creutzfeldt-Jakob disease
 - new variant
 - transfusion-transmitted, 248–249
 - transfusion-transmitted, 248
 - CRIT trial, 181–182
 - Critically ill patients
 - anemia in, **159–178, 225–235**. *See also Anemia, in critically ill patients.*
 - Cytomegalovirus (CMV)
 - transfusion-transmitted, 247
- D**
-
- Damage control surgery, 293
- E**
-
- Elderly
 - transfusions in, 271
 - Epogen
 - as adjunct to transfusion/conservation methods, 288–289
 - Erythropoiesis
 - described, 160
 - in critically ill patients, 160–162
- F**
-
- Febrile nonhemolytic reaction
 - transfusions in ICU and, 240–241
- G**
-
- Graft-versus-host disease
 - transfusion-associated, 244–245
- H**
-
- Hematocrit
 - hemodilution and, 172–173
 - Hemodilution
 - hematocrit and, 172–173
 - Hemolytic anemia, 164–165
 - Hemolytic transfusion reactions
 - transfusions in ICU and, 238–240
 - Hemosiderosis
 - transfusion-related, 245
 - Hemostasis
 - pharmacologic
 - in blood conservation, 318–319
 - Hepatitis
 - transfusion-transmitted, 246–247
 - HIV infection. *See Human immunodeficiency virus (HIV) infection.*
 - Human immunodeficiency virus (HIV) infection
 - transfusion-transmitted, 245–246

I

-
- ICU. *See Intensive care unit (ICU).*
- Immunomodulation
 transfusion-related, 245
- Infection(s)
 emerging
 transfusion-transmitted, 248–249
- Inflammation
 anemia and, 162–164
- Initial sample “waste”
 in anemia of critical illness, 315–316
- Intensive care unit (ICU)
 anemia in, 299–301
 cardiac patients in
 transfusions for, 272–274
 transfusions in
 risk factors for, **237–253**
- Intraoperative blood recovery
 during transfusion, 291–292
- Iron-deficiency anemia, 164

L

-
- “Less-blood surgery,” 292–293

M

-
- Microcirculation
 described, 217–218
 tissue oxygen delivery in, **213–223**.
 See also Tissue oxygen delivery, in microcirculation.
- Military situations
 transfusions in, 282–283
- Mitral valve insufficiency
 transfusions in, 271

O

-
- Oxygen delivery equation, 213
- Oxygen kinetics
 RBC transfusions and, 202–203
- Oxygen transport
 overview of, 187–190

P

-
- Parasitic infections
 transfusion-transmitted, 247–248
- Pathophysiologic processes
 anemia and
 interaction between, 196–202

- Pharmacologic hemostasis
 in blood conservation, 318–319
- Phlebotomy
 and anemia of critical illness, 314–316
 diagnostic
 routine, 314–315
- Phlebotomy tubes
 small volume, 316
- Physiologic response
 tolerance of anemia determined by,
 168–171
- Platelet alloimmunization
 transfusions in ICU and, 244
- Point-of-care bedside microanalysis
 in blood conservation, 317
- Post-transfusion purpura
 transfusions in ICU and, 244

R

-
- RBC. *See Red blood cell (RBC).*
- Recombinant human erythropoietin
 in blood conservation, 318
- Red blood cell (RBC) salvage techniques
 in blood conservation, 317–318
- Red blood Cell (RBC) storage
 in critically ill patients with anemia, 171
- Red blood cell (RBC) transfusions
 for anemia
 microcirculatory effects of,
 195–196
 in critically ill patients
 efficacy of, **255–267**
 oxygen kinetics and, 202–202
- Renal failure
 anemia and, 166

S

-
- Surgery
 bloodless, 290
 transfusions in, **281–296**. *See also Blood transfusion(s), in surgery.*
- Surgery centers
 bloodless, 293

T

-
- Tissue oxygen delivery
 in microcirculation, **213–223**
 central and regional circulations,
 214–217

- in critically ill persons, 219–222
 - physiology of, 214–218
 - Transfusion(s)
 - blood. *See Blood transfusion(s).*
 - for anemia
 - adaptation to, 190–195
 - benefits of, 228–233
 - in critically ill patients, 171
 - in cardiac patients, **269–279**
 - compromised cardiac
 - contractility, 271
 - coronary artery disease, 270–271
 - elderly, 271
 - ICU patients, 272–274
 - mitral valve insufficiency, 271
 - postoperative period, 272
 - triggers for, 274–276
 - in children, **299–311**
 - clinical evidence for, 302–304
 - considerations in, 306–307
 - guidelines for, 304–305
 - risks vs. benefits for, 301–302
 - standards of practice for, 304–306
 - in ICU
 - acute infectious (bacterial),
 - nonimmune reactions to, 243
 - adverse effects of
 - prevalence of, 237–238
 - delayed hemolytic reactions to, 243
 - delayed nonhemolytic reactions to, 244–245
 - diseases transmitted by, 245–248
 - CMV, 247
 - Creutzfeldt-Jakob
 - disease, 248
 - new variant, 248–249
 - emerging infections, 248–249
 - hepatitis, 246–247
 - HIV infection, 245–246
 - parasitic infections, 247–248
 - West Nile virus, 249
 - errors associated with, 249–250
 - graft-versus-host disease and, 244–245
 - hemosiderosis due to, 245
 - immune-mediated reactions to, 238–242
 - allergic transfusion
 - reaction, 241
 - anaphylactic transfusion
 - reactions, 241
 - cardio–respiratory events, 241–242
 - febrile nonhemolytic reaction, 240–241
 - hemolytic transfusion
 - reactions, 238–240
 - immunomodulation due to, 245
 - nonimmune-mediated reactions to, 242–243
 - noninfectious, nonimmune
 - reactions to, 242–243
 - platelet alloimmunization due to, 244
 - post-transfusion purpura and, 244
 - risk factors for, **237–253**
 - future strategies in reduction
 - of, 250
 - RBC
 - for anemia
 - microcirculatory effects of, 195–196
 - in critically ill patients
 - efficacy of, **255–267**
 - Transfusion/conservation methods
 - adjuncts to, 288–289
 - Epogen, 288–289
 - Trauma
 - transfusions due to, **281–296**. *See also Blood transfusion(s), in trauma.*
- W**
-
- West Nile virus
 - transfusion-transmitted, 249